Actively Recruiting
CMV Immunity Monitoring in Lung Transplant Recipients
Led by NYU Langone Health · Updated on 2025-07-30
50
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
Sponsors
N
NYU Langone Health
Lead Sponsor
V
Viracor Eurofins
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.
CONDITIONS
Official Title
CMV Immunity Monitoring in Lung Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
- Pre-existing serological immunity to CMV (R+)
- Able and willing to provide informed consent
You will not qualify if you...
- Received anti-thymocyte globulin induction immunosuppression
- Underwent perioperative desensitization
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
T
Tyler Lewis
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here